Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma
Blood Research
; : 97-102, 2015.
Article
in En
| WPRIM
| ID: wpr-184127
Responsible library:
WPRO
ABSTRACT
BACKGROUND: Few clinical studies have clarified the prognostic factors that affect clinical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy. METHODS: A total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwent positron emission tomography/computed tomography (PET/CT) before and after salvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, and etoposide regimen. Clinical outcomes were compared according to several factors (age > or = 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardized uptake value [SUVmax] or =12 months, complete response after salvage therapy). A low aa-IPI, SUVmax or = 12 months were independent prognostic factors for survival. RESULTS: In univariate analysis and multivariate analysis, SUVmax below 6.0 (P<0.001 for progression-free survival (PFS), P<0.001 for overall survival (OS)) and low aa-IPI (P<0.001 for PFS, P<0.001 for OS) were independent prognostic factors associated with favorable outcome. CONCLUSION: The aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsed or refractory DLBCL.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Recurrence
/
Multivariate Analysis
/
Carboplatin
/
Lymphoma, B-Cell
/
Salvage Therapy
/
Disease-Free Survival
/
Positron-Emission Tomography
/
Electrons
/
Etoposide
/
Positron Emission Tomography Computed Tomography
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Blood Research
Year:
2015
Document type:
Article